

# RHEUMATOLOGY INFUSION REFERRAL FORM



## PATIENT INFORMATION

Last Name	First Name	DOB
Gender	Last 4 SSN	Primary Language
Address		
City	State	ZIP
Email		
Home Phone	Work Phone	Cell Phone
Primary Contact Method (check one)	<input type="checkbox"/> Cell Phone <input type="checkbox"/> Home Phone <input type="checkbox"/> Work Phone <input type="checkbox"/> Text <input type="checkbox"/> Email <input type="checkbox"/> Primary Caregiver <input type="checkbox"/> DO NOT CONTACT	
Primary Caregiver/Alt Contact Name (if applicable)		
Caregiver/Alt Contact Email	Caregiver/Alt Contact Phone	

## PRESCRIBER INFORMATION

Name of Contact Sending Referral	Title
Preferred Contact Method (check one)	Referral Contact Email
<input type="checkbox"/> Email <input type="checkbox"/> Phone <input type="checkbox"/> Fax	
Office Phone	Office Fax
Practice / Facility Name	
Address	
City	State   ZIP
Prescriber Name / Specialty	
Prescriber State License #	DEA #
NPI #	Medicaid UPIN #

## INSURANCE INFORMATION

Insurance Provider	Plan ID #
BIN#:	PCN#:
Insured's Name	RX Group#:
	Relationship to Patient

Eligible for Medicare (check one)	<input type="checkbox"/> Yes <input type="checkbox"/> No	If yes, list Medicare #
Prescription Card (check one)	<input type="checkbox"/> Yes <input type="checkbox"/> No	If yes, list carrier

**Please include a copy of the front and back of insurance card.**

## CLINICAL INFORMATION

Prescription Type	<input type="checkbox"/> Naïve/New Start <input type="checkbox"/> Therapy Restart <input type="checkbox"/> Existing Treatment	Therapy Start Date
Sample/Starter Product Provided?	If yes, Provide Qty	Date Sample Provided
<input type="checkbox"/> Yes <input type="checkbox"/> No		
Allergies <input type="checkbox"/> NKDA <input type="checkbox"/> Drug Allergies (please list)		
Therapies Tried and Failed (please list medications)		
Concurrent Medications		

Patient Height (cm/in)	Patient Weight (kg/lbs)	Date Obtained
Ship to Address <input type="checkbox"/> Home <input type="checkbox"/> Prescriber's Office <input type="checkbox"/> Other (please list)		
ICD-10 Codes	<input type="checkbox"/> M32.8 Other forms of systemic lupus erythematosus <input type="checkbox"/> M32.9 Other forms of systemic lupus erythematosus, unspecified <input type="checkbox"/> M32.10 Systemic lupus erythematosus, organ or system involvement unspecified <input type="checkbox"/> M32.19 Other organ or system involvement in systemic lupus erythematosus <input type="checkbox"/> M05.79 Rheumatoid arthritis with rheumatoid factor of multiple sites w/o organ or systems involvement <input type="checkbox"/> M05.89 Other rheumatoid arthritis with rheumatoid factor of multiple sites <input type="checkbox"/> M06.89 Other specified rheumatoid arthritis, multiple sites <input type="checkbox"/> M06.9 Rheumatoid Arthritis <input type="checkbox"/> Other _____	

We accept Escribe and fax prescriptions.

Phone 855.896.9254 | Fax 855.370.0086

# PRESCRIPTIONS

Patient Last Name	Patient First Name	DOB
-------------------	--------------------	-----

## PRESCRIPTION INFORMATION

MEDICATION	ROUTE	DOSE/STRENGTH	DIRECTIONS	QTY	REFILLS
<input type="checkbox"/> Benlysta	<input type="checkbox"/> IV	<input type="checkbox"/> 10 mg/kg	Starting Dose <input type="checkbox"/> 10 mg/kg IV at week 0, 2, 4 and then every ___ weeks Maintenance Dose <input type="checkbox"/> 10 mg/kg IV every ___ weeks	<input type="checkbox"/> 1 month <input type="checkbox"/> 3 months <input type="checkbox"/> _____	<input type="checkbox"/> 1 year <input type="checkbox"/> _____
<input type="checkbox"/> Cimzia	<input type="checkbox"/> IV	<input type="checkbox"/> 200 mg prefilled syringe <input type="checkbox"/> 200 mg lyophilized powder vial	Starting Dose <input type="checkbox"/> 400 mg (given as two 200 mg subcutaneous injections) at weeks 0,2 and 4 Maintenance Dose <input type="checkbox"/> 200 mg subcutaneous injection every other week <input type="checkbox"/> Other _____	<input type="checkbox"/> 1 month <input type="checkbox"/> 3 months <input type="checkbox"/> _____	<input type="checkbox"/> 1 year <input type="checkbox"/> _____
<input type="checkbox"/> Orencia (abatacept)	<input type="checkbox"/> IV	<input type="checkbox"/> 500 mg Orencia <input type="checkbox"/> 750 mg Orencia <input type="checkbox"/> 1000 mg Orencia	<input type="checkbox"/> Infuse over 30 minutes	<input type="checkbox"/> 1 month <input type="checkbox"/> 3 months <input type="checkbox"/> _____	<input type="checkbox"/> 1 year <input type="checkbox"/> _____
<input type="checkbox"/> Remicade (infliximab)	<input type="checkbox"/> IV	Starting Dose <input type="checkbox"/> 5 mg/kg ___mg IV at week 0,2,6 <input type="checkbox"/> 3 mg/kg ___mg IV at week 0,2,6 <input type="checkbox"/> Other _____ Maintenance Dose <input type="checkbox"/> 2 mg/kg ___mg IV every 8 weeks <input type="checkbox"/> Other _____	<input type="checkbox"/> To be infused over a period NOT less than 2 hours	<input type="checkbox"/> 1 month <input type="checkbox"/> 3 months <input type="checkbox"/> _____	<input type="checkbox"/> 1 year <input type="checkbox"/> _____
<input type="checkbox"/> Rituxin	<input type="checkbox"/> IV	<input type="checkbox"/> 1000 mg IV on day 0, day 14 and then repeat the course every ___ weeks <input type="checkbox"/> 375 mg/m2 IV every 4 weeks <input type="checkbox"/> Other _____	<input type="checkbox"/> Infuse as directed	<input type="checkbox"/> 1 month <input type="checkbox"/> 3 months <input type="checkbox"/> _____	<input type="checkbox"/> 1 year <input type="checkbox"/> _____
<input type="checkbox"/> Simponi Aria (golimumab)	<input type="checkbox"/> IV	Starting dose <input type="checkbox"/> 2 mg/kg ___mg IV at week 0, 4 and every 8 weeks <input type="checkbox"/> Other _____ Maintenance Dose <input type="checkbox"/> 2 mg/kg ___mg IV every 8 weeks <input type="checkbox"/> Other _____	<input type="checkbox"/> Infuse diluted solution over a period of 30 minutes	<input type="checkbox"/> 1 month <input type="checkbox"/> 3 months <input type="checkbox"/> _____	<input type="checkbox"/> 1 year <input type="checkbox"/> _____

See next page for additional medications.

**Patient Support Programs: Please have patient sign and date to enroll in pharmaceutical company assisted support program.**

_____	____ / ____ / ____	_____
Patient Signature	Date	Account Manager

**Prescriber Authorization (No stamps. Signature and date must be completed in prescriber's handwriting.)**

_____	____ / ____ / ____
Prescriber Signature	Date

_____	____ / ____ / ____
Supervising Physician Signature (Dispense as Written)	Date

**\*\*The information contained in this document will become a legal prescription. Follow all state Medical Board guidelines when completing, inclusive of guidelines that pertain to the number of prescriptions allowed on a single prescription form. If more than one page is required, make additional copies. Use state board mandated language for dispensing brand name medications or generic substitution and follow physician signature requirements.**

**Confidentiality Statement:** This message is intended only for the individual or entity to which it is addressed. It may contain information which may be proprietary and confidential. It may also contain privileged, confidential information which is exempt from disclosure under applicable laws, including the Health Insurance Portability and Accountability Act (HIPAA). If you are not the intended recipient, please note that you are strictly prohibited from disseminating or distributing this information (other than to the intended recipient) or copying this information. If you received this communication in error, please notify the sender immediately at the address and telephone number set forth herein and obtain instructions as to proper destruction of the transmitted material.

# PRESCRIPTIONS

Patient Last Name	Patient First Name	DOB
-------------------	--------------------	-----

## PRESCRIPTION INFORMATION

MEDICATION	ROUTE	DOSE/STRENGTH	DIRECTIONS	QTY	REFILLS
<input type="checkbox"/> Normal Saline <input type="checkbox"/> D5W	<input type="checkbox"/> IV	<input type="checkbox"/> 3 mL <input type="checkbox"/> 5 mL <input type="checkbox"/> _____	<input type="checkbox"/> Before and after infusion <input type="checkbox"/> _____	<input type="checkbox"/> 1 month <input type="checkbox"/> 3 months <input type="checkbox"/> _____	<input type="checkbox"/> 1 year <input type="checkbox"/> _____
<input type="checkbox"/> Heparin 10 units/mL <input type="checkbox"/> Heparin 100 units/mL	<input type="checkbox"/> IV	<input type="checkbox"/> 3 mL <input type="checkbox"/> 5 mL <input type="checkbox"/> _____	<input type="checkbox"/> After infusion <input type="checkbox"/> _____	<input type="checkbox"/> 1 month <input type="checkbox"/> 3 months <input type="checkbox"/> _____	<input type="checkbox"/> 1 year <input type="checkbox"/> _____
<input type="checkbox"/> Diphenhydramine	<input type="checkbox"/> PO <input type="checkbox"/> IV <input type="checkbox"/> IM	<input type="checkbox"/> 25 mg <input type="checkbox"/> 50 mg <input type="checkbox"/> _____	<input type="checkbox"/> After infusion <input type="checkbox"/> PRN Allergic Reaction: _____ <input type="checkbox"/> _____	<input type="checkbox"/> With each infusion <input type="checkbox"/> _____	<input type="checkbox"/> 1 year <input type="checkbox"/> _____
<input type="checkbox"/> Acetaminophen	<input type="checkbox"/> PO	<input type="checkbox"/> 325 mg <input type="checkbox"/> 500 mg <input type="checkbox"/> 650 mg <input type="checkbox"/> 1 gm <input type="checkbox"/> _____	<input type="checkbox"/> Pre-Med: _____ <input type="checkbox"/> _____	<input type="checkbox"/> With each infusion <input type="checkbox"/> _____	<input type="checkbox"/> 1 year <input type="checkbox"/> _____
<input type="checkbox"/> Epinephrine	<input type="checkbox"/> IM <input type="checkbox"/> SQ	<input type="checkbox"/> Adult 1:1000, 0.3 mL (>30kg/>66lbs) <input type="checkbox"/> Peds 1:2000, 0.3 mL (15-30kg/33-66lbs)	<input type="checkbox"/> PRN Anaphylaxis <input type="checkbox"/> Repeating Dose: _____	<input type="checkbox"/> Once <input type="checkbox"/> _____	<input type="checkbox"/> 1 year <input type="checkbox"/> _____
<input type="checkbox"/> Other:	<input type="checkbox"/> _____				
<input type="checkbox"/> Vascular Access Method	<input type="checkbox"/> peripheral <input type="checkbox"/> central <input type="checkbox"/> other: _____				

Total RXs \_\_\_\_\_

**Lab Orders \_\_\_\_\_**  
 Skilled nursing visits as needed to establish venous access administer medication and assess general status and response to therapy. Dispense 1 month of drug, flushes, needles, syringes, ancillary supplies and medical equipment necessary to establish access and administer medication. Prescription to include all necessary ancillary supplies (needle, syringes, etc). If shipped to physician's office, physician accepts on behalf of patient for administration in office.

**Patient Support Programs: Please have patient sign and date to enroll in pharmaceutical company assisted support program.**

	____ / ____ / ____	
Patient Signature	Date	Account Manager

**Prescriber Authorization (No stamps. Signature and date must be completed in prescriber's handwriting.)**

	____ / ____ / ____
Prescriber Signature	Date
	____ / ____ / ____
Supervising Physician Signature (Dispense as Written)	Date

**\*\*The information contained in this document will become a legal prescription. Follow all state Medical Board guidelines when completing, inclusive of guidelines that pertain to the number of prescriptions allowed on a single prescription form. If more than one page is required, make additional copies. Use state board mandated language for dispensing brand name medications or generic substitution and follow physician signature requirements.**

*Confidentiality Statement: This message is intended only for the individual or entity to which it is addressed. It may contain information which may be proprietary and confidential. It may also contain privileged, confidential information which is exempt from disclosure under applicable laws, including the Health Insurance Portability and Accountability Act (HIPAA). If you are not the intended recipient, please note that you are strictly prohibited from disseminating or distributing this information (other than to the intended recipient) or copying this information. If you received this communication in error, please notify the sender immediately at the address and telephone number set forth herein and obtain instructions as to proper destruction of the transmitted material.*